{"id":"NCT03476135","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children","officialTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-27","primaryCompletion":"2018-09-10","completion":"2018-09-10","firstPosted":"2018-03-23","resultsPosted":"2020-06-05","lastUpdate":"2022-04-06"},"enrollment":91,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"MenACYW conjugate vaccine","otherNames":[]}],"arms":[{"label":"Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)","type":"EXPERIMENTAL"},{"label":"Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)","type":"EXPERIMENTAL"}],"summary":"This was an open-label, multi-center study to describe the immune persistence of the priming dose and describe the immunogenicity and safety of a booster dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) conjugate vaccine in children in Finland who had been vaccinated 3 years earlier as toddlers with either MenACYW conjugate vaccine or Nimenrix® as part of the MET54 study (NCT03205358).\n\nThe objectives were:\n\n* To describe the antibody persistence of meningococcal serogroups A, C, Y, and W before a booster dose in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.\n* To describe the antibody responses to meningococcal serogroups A, C, Y, and W 30 days after a booster dose of MenACYW conjugate vaccine in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.\n* To describe the antibody responses against tetanus toxoid 30 days after a booster dose of MenACYW conjugate vaccine in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.\n* To describe the safety profile of a booster dose of MenACYW conjugate vaccine in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.","primaryOutcome":{"measure":"Antibody Titers Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW Conjugate Vaccine in MET62","timeFrame":"Day 0 (pre-vaccination)","effectByArm":[{"arm":"Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)","deltaMin":12.1,"sd":null},{"arm":"Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)","deltaMin":16.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"46 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":8,"countries":["Finland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":["Injection Site Pain","Injection Site Erythema","Injection Site Swelling","Myalgia","Malaise"]}}